Vincent S. LoPriore, Executive Chairman, 10% Owner at Hepion Pharmaceuticals, Inc. (HEPA), bought 6,250,000 shares at $0.04 ($250K) on 2026-04-21, disclosed to the SEC on 2026-04-27.
Executive Chairman Vincent S. LoPriore purchased $200,000 of stock at $0.04, marking the largest insider purchase in the company's history and signaling strong conviction in the current valuation. This high-volume buy from a 10% stakeholder suggests the executive believes the stock is significantly undervalued relative to its potential.
HEPA is trading at its 52-week high of $0.3181, having gained 3% over the last 30 days and sitting just 3% above its 52-week low of $0.318. The stock is currently flat over the last 5 days, consolidating near the top of its recent range.
Insider cluster: This is the largest insider purchase ever recorded for Hepion; track this momentum as a signal of conviction. Short interest: With 4.1% of the float sold short, a sustained insider buying push could trigger a short squeeze.
Valuation: The company trades at a negative forward P/E of -0.0066, indicating a lack of profitability and potential cash burn concerns. Sector: The industry has seen net selling pressure over the last 90 days (-0.43% buy percentage), creating a divergence between insider sentiment and broader market activity.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.04 | 1,250,000 | $50K | 20.0% |
| 2 | $0.04 | 5,000,000 | $200K | 80.0% |
| Total | $0.04 avg | 6,250,000 | $250K | 100% |